top of page

See what our clients are saying:

Amorphex Therapeutics LLC

Kathy has worked with Amorphex Therapeutics since 2006, helping to guide overall development of our topical drug delivery device, managing preclinical and clinical studies, and providing regulatory guidance, as well as assisting with grant funding and publications/presentations. Her flexibility in working with our small, emerging company has been an invaluable resource.

Charles D. Leahy, O.D., M.S.

Founder, VP of Clinical Affairs

Amorphex Therapeutics LLC

Integral BioSystems LLC

Dr. Kathryn Crawford is one of the most versatile scientists I have ever met. Her knowledge and expertise spans across R&D preclinical exploration studies to designing toxicology studies for ophthalmic drug products, to CMC development. She is an ophthalmic pharmacologist by formal training, but has managed and run drug development in multiple disciplines. She has an easy demeanor and approachable; she is great to have in the team. I have worked with her in multiple programs and I recommend her highly.

Shikha P. Barman, Ph.D.

Chief Executive Officer

Integral BioSystems, LLC

Encore Vision Inc

Develop a customized, streamlined plan to get you quickly though clinical POC and efficiently manage your program and timelines.

Let's start planning together today.

Pharmacology &

Support services for animal disease models, drug delivery, irritation screening/ formulation and toxicology study placement & support.

CMC/Formulation Development

Ophthalmic formulation development, device/drug release studies, clinical manufacturing placement and support.


Provide regulatory support and strategic planning including  Pre-IND support briefing books, and

IND Preparation.

Are development timelines closing in on you?

Look to PharmOcu to help you meet every milestone.

Kathy provided basic science, pre-clinical, CMC and clinical services to Encore Vision as the Company pioneered R&D for a first in class topical pharmaceutical treatment for presbyopia.  As a topical treatment for presbyopia had not before been developed and tested in the clinic, much creative application of her knowledge and skills was integral to the successful outcome of the project to date, including successful outcome of a Phase 1 – 2 clinical study and sale of the technology to Novartis.  I would highly recommend Kathy to support R&D to any company, especially small and start-ups.  Kathy will certainly prove to be an asset and great team member.

William Burns
President & CEO
Encore Vision, Inc.

bottom of page